there is no information available on effect of enoxaparin or metabolites on breastfed child, or on milk production; developmental and health benefits of breastfeeding should be considered along with mother's clinical need for therapy and any potential adverse effects on breastfed child from drug or...
No long-term studies in animals have been performed to evaluate the carcinogenic potential of enoxaparin. Enoxaparin was not mutagenic in in vitro tests, including the Ames test, mouse lymphoma cell forward mutation test, and human lymphocyte chromosomal aberration test, and the in vivo rat bone m...
Precautions Enoxaparin Sodium should be used with a caution in conditions with increased potential for bleeding, such as impaired hemostasis, history of peptic ulcer, recent ischemic stroke, uncontrolled severe arterial hypertension, diabetic retlnopathy and recent neuro or opthalmologic surgery (see ...
Administer postoperative anticoagulation with caution and only when hemostasis achieved because of the potential for bleeding at surgical site. In patients undergoing procedures associated with high risk of bleeding, ACCP suggests delaying the resumption of therapeutic-dose enoxaparin until 48–72 hours ...
The immunogenic potential of LMWHs varies in terms of ability to generate A-HPF4-Ab, the antibody subtypes generated, and their cross-reactivity with pre-formed A-HPF4-Ab. Such parameters may be useful in defining the bioequivalence of generic LMWHs. Future studies evaluating the immunogenicity...
The type of difference between the Teva enoxaparin and the originator enoxaparins identified in the current study clearly show the potential need to include AT-affinity chromatography as a key step in the characterization of LMWHs. Despite the differences attributed to the manufacturing processes, it...